IMFINZI® (Durvalumab) Approved in the US As First and Only Perioperative Immunotherapy for Patients with Muscle-Invasive Bladder Cancer

Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC

"This is another tool in our armamentarium to treat muscle-invasive bladder cancer and represents an advance compared to where we've been over the past few decades," says Matthew D. Galsky, MD.

IMFINZI® (Durvalumab) Approved in the US As First and Only Perioperative Immunotherapy for Patients with Muscle-Invasive Bladder Cancer

AstraZeneca’s Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer. [Astrazeneca] Press Release

The head of the Unit of Genitourinary Tumors of the Medical Oncology Service of the Hospital Marqués de Valdecilla de Santander, Dr. Ignacio Durán, has asked to accelerate access to pharmacological innovation to optimize the treatment of advanced kidney cancer in Spain, a measure that must be accompanied by public funding of combined therapies.

Dr Galsky on Durvalumab's FDA Approval in Muscle-Invasive Bladder Cancer

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.